The global bronchodilators market is projected to expand at a CAGR of 4.5% during the forecast period of 2023 and 2031. The bronchodilators market is developing due to factors such as the increasing elderly population, the rising prevalence of lung disorders, and the rising awareness of lung disease treatment, which is assisted by the increasing R&D efforts of market leaders. Due to the off-label usage of bronchodilators for inpatient treatment, the COVID-19 outbreak had a beneficial effect on the market. In addition, SARS-CoV-2 weakened patients' lungs and immune systems, making them prone to lung illnesses and viral infections. In 2020, according to the NCBI, 83% of adult wheezing exacerbations would be caused by rhinovirus, which will increase the demand for nebulizers.
Increasing Geriatric Population
As the aged population has a mortality rate that is five times greater than the general population due to asthma, bronchodilators are projected to play a crucial role in driving the market forward. In addition, the number of persons aged over 65 is forecast to increase by 2025, which is likely to contribute to the profitability of the bronchodilators market. In addition, the increased prevalence of respiratory illnesses around the world is a crucial factor in the development of innovative goods. By expanding the airways and counteracting the effects of an attack, bronchodilators assist alleviate the symptoms of respiratory illnesses such as asthma and COPD. This is resulting in a spike in product approvals and releases for the treatment and management of respiratory illnesses, which is anticipated to contribute to the segment's growth.
Slower Approvals to Constrain Market Growth
However, the market for bronchodilators is considerably limited by the regulatory system. When safety issues develop, the regulatory approval procedure is frequently criticized for being unduly slow or lax. As dependence on bronchodilators increases, the regulatory environment is already complex, and the FDA is becoming more vigilant. Therefore, the stringent constraints involved with the bronchodilator approval procedure are constraining market growth. In addition, the U.S. faced a scarcity of albuterol inhalers in December 2023, indicating an unmet demand that can be met by new generic firms.
Innovations to Drive to Market During the Forecast Period
According to data published by the Centers for Disease Control and Prevention (CDC), approximately 4,069,278 Americans aged 65 and over had asthma in 2019. Due to the importance of bronchodilators in maintaining adequate airflow within the lungs of these patients, the demand for bronchodilators is projected to increase in the near future. In addition, an increase in the number of product launches and approvals is anticipated to have a beneficial effect on the demand for bronchodilators among the patient population. For example, in July 2020, EVA Pharma introduced 'Inhalex,' the first Egyptian drug with a 24-hour duration of effect for COPD. The introduction of this medicine is anticipated to cut in half the cost of treating COPD patients. In contrast, certain adverse effects such as tremors, coughing, an elevated heart rate, and anxiousness are projected to impede market expansion over the projection period.
Beta-adrenergic Bronchodilators Dominate the Market
The beta-adrenergic bronchodilators category dominated the market in 2023 with a revenue share of over 38% and is anticipated to develop at the fastest CAGR of 3.5 % over the forecast period. In order to dilate the bronchial airways, beta-adrenergic bronchodilators relax the muscles that surround the airways. This category of drugs is beta-2 agonists that target smooth muscle cell receptors for airway dilatation. Levalbuterol (Xopenex HFA), albuterol (Proair HFA, Proventil HFA, AccuNeb, Ventolin HFA), and epinephrine injection are major short-acting products. Albuterol is the top revenue-generating molecule in this category, and the FDA is observing an increasing number of generic approvals and new product launches for this molecule to meet increased demand. In May of 2023, for instance, Teva Pharmaceutical Industries Ltd. highlighted the potential of ProAir Digihaler (albuterolsulfate) inhalation powder for the treatment of asthmatic patients.
The market of anticholinergic bronchodilators is anticipated to have a lucrative growth rate throughout the forecast period. The segment's expansion is attributable to the availability of both long- and short-acting anticholinergic formulations. In addition, anticholinergic bronchodilators prevent parasympathetic nerve reflexes from constricting the airways, so keeping the airways open. Commonly, chronic obstructive pulmonary disease (COPD) is treated with anticholinergic bronchodilators, which are considered the first-line treatment for COPD. Anticholinergics are associated with a 60% increase in fall-related hospitalizations, a 50% rise in dementia risk, and a 30% increase in mortality, particularly among the elderly, which hinders the segment's growth.
Nasal Segmented Contributed to more than 50% of revenues for the Market by Administration Route
The nasal (Inhalable) segment held the biggest market share of 52% in 2023 and is anticipated to grow at the quickest CAGR of 3.3 % during the projected period. The most common mode of administration for bronchodilators is the nasal or inhalational route. This route of administration is commonly utilized with metered-dose inhalers (MDIs), nebulizers, dry powder inhalers, and soft mist inhalers. According to a study published in the International Journal of Chronic Obstructive Pulmonary Disease, soft mist inhaler aerosol gives a slower-moving and longer-lasting dosage than MDI. In addition, the introduction of a generic version of nasal formulations is accelerating market expansion. For instance, in March 2023, the FDA approved Mylan's first generic version of Symbicort, an inhaled aerosol used to treat asthma and COPD.
The oral segment is anticipated to have profitable expansion throughout the projection period. The segment's market share is driven by the fact that it is the second most favored form of administration among doctors and patients, who prefer to avoid the undesirable effects of injectable administration. In addition, they are typically less expensive with many generic alternatives accessible on the market, and they are the second most favored form of administration among physicians and patients since they avoid the undesirable effects of injectable administration.
Asthma Segment Dominated the Market by Disease
The asthma sector held the biggest revenue share of 42% in 2023 and grew at the quickest CAGR of 3.31 % during the forecast period. The segment's dominance can be ascribed to the rising prevalence of asthma in the population. The World Health Organization estimates that asthma affects 262 million persons worldwide, with inflammation and bronchial constriction being common symptoms. The segment's research pipeline is robust, with numerous candidates in late- or mid-stage development. Multiple double and triple combination inhalers for asthma are also in the last phases of development, with the aim of improving treatment adherence. PT027 (Albuterol/Budesonide Fixed-Dose Combo), developed through a collaboration between AstraZeneca and Avillion, exhibited good results in Phase III clinical trials and was accepted by the FDA as a new medication application submitted by both companies in May 2023.
The Chronic obstructive pulmonary disease (COPD) market segment is anticipated to grow profitably over the next years. As a result of the increase in the elderly population, it is anticipated that the need for COPD medications will also increase. Individuals older than 65 have an increased chance of acquiring COPD. COPD has a lesser frequency than asthma, yet causes 5% of fatalities worldwide. A high prevalence of COPD is also related to a high rate of overdiagnosis. The disease is prevalent in low- and middle-income nations and has a high fatality rate.
North America remains the Global Leader
In 2023, North America dominated the bronchodilators market due to the increasing prevalence of COPD and asthma, the rising elderly population, and the rising demand for high-efficacy and fast-acting medications in the area. Air pollution, working with chemicals, dust and fumes, passive smoking, and a history of childhood lung illness all contribute to the increase in COPD incidence in the region. According to the American Lung Association, 85 to 90 percent of COPD cases are caused by cigarette smoking. The region has a large population of smokers, estimated at 30,8 million individuals in the United States, and more than 16 million residents suffer from smoking-related illnesses.
The United States has held the largest market share in North America and is likely to continue to do so during the projection period. Chronic Obstructive Pulmonary Disease (COPD) affects millions of Americans annually and is the third leading cause of death in the United States due to disease. In 2018, roughly 16.4 million adults in the United States reported a diagnosis of COPD, according to data published by the American Lung Association (emphysema, chronic bronchitis, or COPD). Similarly, asthma remains a significant societal concern in the United States. In April 2021, the Environmental Protection Agency and the National Health Interview Surveys (NHIS) estimated that around 25.1 million Americans, including 5.1 million children, have asthma. In 2019, over 10.3 million persons with asthma, including approximately 2.3 million children, report having experienced one or more asthma attacks, according to the same source. Since bronchodilators are typically the first-line treatment for respiratory-related problems, North America is predicted to be the largest contributor to revenue throughout the forecast period. In addition, an increase in the number of smokers in the region and a dramatic rise in environmental pollution are other factors driving the expansion of the bronchodilator industry. Similarly, persistent R&D efforts by regional market participants to create an effective treatment for individuals with respiratory problems are anticipated to drive market expansion. For instance, the American biotechnology company Regeneron Pharmaceuticals, Inc. worked with Sanofi to explore pediatric asthma. The therapeutic candidate is now undergoing Phase III clinical trials, which are anticipated to conclude in September 2021. Consequently, the expansion of the bronchodilators market in North America can be attributed to the aforementioned factors.
Asia-Pacific to be The Growth Leader During the Forecast Period
Asia-Pacific is anticipated to be the fastest-growing region during the projected time frame. The region has a high asthma prevalence. Asthma is one of the main causes of death and a major noncommunicable disease in the region, according to reports. In addition, the existence of significant businesses like Glenmark Pharmaceuticals Limited and Cipla Inc. gives the region a competitive edge, as these companies specialize in low-cost generic bronchodilators. In addition, the introduction of improved inhaler bronchodilators is driving market expansion. For instance, in October 2020, Zydus Cadila introduced its pressurized metered-dose inhaler, ForglynpMDI, for COPD patients in India at a price of Rs 495 per pack.
Competition to Intensify During the Forecast Period
The market leaders in bronchodilators are emphasizing partnerships, geographic expansion, and strategic collaborations in emerging and economically beneficial regions. In October 2023, for instance, AeroRx Therapeutics teamed with HCmed Innovations to create a unique therapeutic combination of bronchodilators for the treatment of COPD. The market for bronchodilators is very competitive, with a number of major global players. In terms of market share, the market is now dominated by numerous significant competitors. With increasing patient awareness and the incidence of respiratory disorders, it is anticipated that numerous regional players would participate in the bronchodilators market over the projection period. Teva Pharmaceutical Industries Ltd., Novartis AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Cipla Inc., and AstraZeneca are among the market's leading participants.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Bronchodilator market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Drug Class
| |
Route of Administration
| |
Disease
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
